SG11201811807XA - Dairy product and process - Google Patents

Dairy product and process

Info

Publication number
SG11201811807XA
SG11201811807XA SG11201811807XA SG11201811807XA SG11201811807XA SG 11201811807X A SG11201811807X A SG 11201811807XA SG 11201811807X A SG11201811807X A SG 11201811807XA SG 11201811807X A SG11201811807X A SG 11201811807XA SG 11201811807X A SG11201811807X A SG 11201811807XA
Authority
SG
Singapore
Prior art keywords
international
permeate
produce
retentate
dairy
Prior art date
Application number
SG11201811807XA
Inventor
Alan David Welman
Geoffrey Stevens
Christopher Paul Mcjarrow
Bertram Yin Fong
Bing Wang
Original Assignee
Fonterra Cooperative Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fonterra Cooperative Group Ltd filed Critical Fonterra Cooperative Group Ltd
Publication of SG11201811807XA publication Critical patent/SG11201811807XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1206—Lactose hydrolysing enzymes, e.g. lactase, beta-galactosidase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K13/00—Sugars not otherwise provided for in this class
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2210/00—Physical treatment of dairy products
    • A23C2210/20—Treatment using membranes, including sterile filtration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2210/00—Physical treatment of dairy products
    • A23C2210/20—Treatment using membranes, including sterile filtration
    • A23C2210/206—Membrane filtration of a permeate obtained by ultrafiltration, nanofiltration or microfiltration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Pediatric Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property :::` , 111111111111111111111111111 01111101 0111101 010H011110 1111 00 1111111 111111111111 Organization International Bureau (10) International Publication Number 03 (43) International Publication Date .....•\"\" WO 2018/020473 Al 01 February 2018 (01.02.2018) W I P0 I P C T (51) International Patent Classification: [AU/AU]; 26 Traynor Ave, NSW, Kogarah, New South A61K 31/702 (2006.01) A23C 9/12 (2006.01) Wales 2217 (AU). A23C 9/142 (2006.01) A61P 25/00 (2006.01) (74) Agent: AJ PARK; Level 22, State Insurance Tower, 1 (21) International Application Number: Willis Street, Wellington, 6011 (NZ). PCT/IB2017/054610 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 28 July 2017 (28.07.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (30) Priority Data: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 722642 28 July 2016 (28.07.2016) NZ MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: FONTERRA CO-OPERATIVE GROUP SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, LIMITED [NZ/NZ]; 109 Fanshawe Street, Auckland, 1010 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (NZ). (84) Designated States (unless otherwise indicated, for every (72) Inventors; and kind of regional protection available): ARIPO (BW, GH, (71) Applicants: WELMAN, Alan David [NZ/NZ]; Dairy GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, _ Farm Road, Fitzherbert, Palmerston North (NZ). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, STEVENS, Geoffrey [NZ/NZ]; Dairy Farm Road, Fitzher- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, bert, Palmerston North (NZ). MCJARROW, Christopher EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = Paul [NZ/NZ]; Dairy Farm Road, Fitzherbert, Palmerston MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, North (NZ). FONG, Bertram Yin [NZ/NZ]; Dairy Farm TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, =_ Road, Fitzherbert, Palmerston North (NZ). WANG, Bing KM, ML, MR, NE, SN, TD, TG). = (54) Title: DAIRY PRODUCT AND PROCESS = (57) : A method of producing sialyloligosaccharides a sialyloligosaccharides-contain- = = ing source that also contains carbohydrates and minerals. The process includes subjecting the [ '''''' 7, = \"''' \" = 1 source to a temperature of from about 67°C and (i) filtration with a heat-resistant filter at a tem- [ Heating stag I perature of about 35 to about 95°C to produce a first retentate and first permeate, or (ii) cen- 1 1 trifugal separation to produce a light phase and a heavy phase and filtration of the light phase = at a temperature of about 50 to about 70°C to produce a first retentate and first permeate, (b) 1 1 , 1 • nanofiltration of the first permeate, or nanofiltration and diafiltration of the first permeate, to produce a second retentate and second permeate, and (c) concentration of the second retentate, to produce a sialyloligosaccharide-containing extract. Additionally, the invention relates to a sialy- loligosaccharide-enriched composition comprising at least 3'-sialyllactose and 6'-sialyllactose- = _ [ , 11. =:=7 = 1 = its in, for infant formulas, and for improving NF/DF and use example, nutritional and maintaining or = 1 cognitive function. NF or RO / = Evaporation [ ] I Enzyme reaction Il OecolOY / M Filtration I Ir ... ' 7r ( containm9 liquid extract 1 © ei © cc [ ° '\"g 1 1 containing dry extract 1-1 ei C [Continued on next page] WO 2018/020473 Al O II Published: — with international search report (Art. 21(3))
SG11201811807XA 2016-07-28 2017-07-28 Dairy product and process SG11201811807XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ72264216 2016-07-28
PCT/IB2017/054610 WO2018020473A1 (en) 2016-07-28 2017-07-28 Dairy product and process

Publications (1)

Publication Number Publication Date
SG11201811807XA true SG11201811807XA (en) 2019-02-27

Family

ID=61017021

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202100843TA SG10202100843TA (en) 2016-07-28 2017-07-28 Dairy product and process
SG11201811807XA SG11201811807XA (en) 2016-07-28 2017-07-28 Dairy product and process

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202100843TA SG10202100843TA (en) 2016-07-28 2017-07-28 Dairy product and process

Country Status (13)

Country Link
US (2) US10729707B2 (en)
EP (1) EP3490567A4 (en)
JP (1) JP2019523278A (en)
KR (1) KR102502459B1 (en)
CN (1) CN109715169A (en)
AU (1) AU2017302181B2 (en)
BR (1) BR112019001525B1 (en)
CA (1) CA3030809A1 (en)
MX (1) MX2019000881A (en)
NZ (1) NZ750365A (en)
RU (1) RU2019105567A (en)
SG (2) SG10202100843TA (en)
WO (1) WO2018020473A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202011734QA (en) * 2018-06-01 2020-12-30 Jennewein Biotechnologie Gmbh A simple method for the purification of a sialyllactose
EP3686210A1 (en) 2019-01-24 2020-07-29 DuPont Nutrition Biosciences ApS Process for purifying a human milk oligosaccharide and related compositions
BE1027078A9 (en) * 2019-02-25 2020-09-28 Nutribam Bvba COMPOSITION, NUTRITIONAL SUPPLEMENT AND PROCEDURE FOR SUPPORTING AND / OR IMPROVING GUT HEALTH
US20220022515A1 (en) 2019-02-25 2022-01-27 Nutribam Bv Composition, Food Supplement and Method for Supporting and/or Improving Intestinal Health
EP3934657A4 (en) * 2019-03-05 2023-01-04 Glycom A/S Human milk oligosaccharides for use in enhancing executive function
EP3741770A1 (en) 2019-05-21 2020-11-25 Jennewein Biotechnologie GmbH Purification of oligosaccharides from a fermentation broth by using filtration
CN110839698A (en) * 2019-11-29 2020-02-28 内蒙古伊利实业集团股份有限公司 Composition and food application thereof
EP4069824A1 (en) * 2019-12-02 2022-10-12 Avant Meats Company Limited Methods of meat production by in vitro cell cultivation
US20230030220A1 (en) * 2019-12-19 2023-02-02 Glycom A/S Separation of sialylated oligosaccharides from fermentation broth
CN112655774A (en) * 2020-12-25 2021-04-16 石家庄君乐宝乳业有限公司 Infant formula milk powder for promoting brain development and preparation method and application thereof
WO2023025797A1 (en) * 2021-08-24 2023-03-02 Dsm Ip Assets B.V. Human milk oligosaccharides and vitamin b12 composition
WO2023025799A1 (en) * 2021-08-24 2023-03-02 Dsm Ip Assets B.V. Human milk oligosaccahrides in cosmetics
CN114014896B (en) * 2021-10-09 2023-12-05 中国科学院合肥物质科学研究院 Separation and purification method of high-purity 3' -sialyllactose
KR20230119870A (en) 2022-02-08 2023-08-16 주식회사 케이제이엠바이오 Method for preparing a composition for improving brain function and food and pharmaceutical composition for improving brain function
CN114831198B (en) * 2022-05-25 2024-01-30 江南大学 Method for increasing organic acid in Kangpu tea by adding milk permeate powder

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5575916A (en) 1994-11-07 1996-11-19 Neose Pharmaceuticals, Inc. Method of processing a cheese processing waste stream
JP2997419B2 (en) * 1996-05-31 2000-01-11 雪印乳業株式会社 Brain ganglioside content decrease inhibitor
NZ335203A (en) 1996-10-10 2000-10-27 Neose Technologies Inc Carbohydrate, purification using ultrafiltration, reverse osmosis and nanofiltration
DK2241616T3 (en) * 1997-08-21 2013-02-18 New Zealand Dairy Board Immune-enhancing lactic acid bacteria
JPH11180993A (en) * 1997-12-19 1999-07-06 Snow Brand Milk Prod Co Ltd Production of sialic acid
US6288222B1 (en) * 2000-02-16 2001-09-11 Neose Technologies, Inc. Method of filtration of a dairy stream
US6623954B1 (en) * 2002-05-28 2003-09-23 Neose Technologies, Inc. Process for removal of phosphorous from a dairy stream
RU2442438C2 (en) 2005-02-21 2012-02-20 Нестек С.А. Mixture of oligasaccharides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007051475A1 (en) 2005-11-04 2007-05-10 Arla Foods Amba A concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof
BRPI0909289A2 (en) 2008-03-14 2015-08-04 Nestec Sa Symbiotic Mixture
NL2001377C2 (en) 2008-03-14 2009-09-15 Friesland Brands Bv Process for isolating sialic acid-containing oligosaccharides, as well as the compositions containing sialic acid-containing oligosaccharides.
EP2147678A1 (en) 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
GB2468670A (en) 2009-03-17 2010-09-22 Separation Technologies Invest Processing whey or raw milk
ES2651067T3 (en) 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibition of inflammation with milk oligosaccharides
JP5599994B2 (en) 2009-09-29 2014-10-01 雪印メグミルク株式会社 Separation method of sialyl lactose material
JP5641598B2 (en) * 2009-09-29 2014-12-17 雪印メグミルク株式会社 Separation method of sialyl lactose material
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
SG183978A1 (en) 2010-03-12 2012-10-30 Dsm Ip Assets Bv Maternal sialic acid supplementation
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
WO2012092160A2 (en) 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
CN104126749A (en) 2011-02-10 2014-11-05 雀巢产品技术援助有限公司 Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US20120276208A1 (en) 2011-04-27 2012-11-01 University Of South Australia Acute cognitive and mood effects of plant polysaccharides in adult human subjects
US9382564B2 (en) 2011-05-13 2016-07-05 Glycom A/S Diversification of human milk oligosaccharides (HMOs) or precursors thereof
EP2526784A1 (en) * 2011-05-24 2012-11-28 Nestec S.A. Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
BR112014008944B1 (en) 2011-10-18 2020-09-15 Société des Produits Nestlé S.A. SYMBOTIC NUTRITIONAL COMPOSITION UNDERSTANDING LC-PUFA, PROBIOTIC AND OLIGOSACARIDE MIXTURE FOR BRAIN GROWTH AND / OR COGNITIVE AND / OR PSYCHOMOTOR DEVELOPMENT
WO2013154725A1 (en) 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
ES2795665T3 (en) 2012-09-14 2020-11-24 Abbott Lab Procedures to increase brain functionality using 2-fucosyl-lactose
CN107853705A (en) * 2012-11-02 2018-03-30 N·V·努特里奇亚 For improving the Synbiotic combination of brain
US20140170293A1 (en) * 2012-12-13 2014-06-19 Arla Foods Amba Concentrate Derived from a Milk Product Enriched in Naturally Occurring Sialyllactose and a Process for Preparation Thereof
CN104955344A (en) 2012-12-18 2015-09-30 雅培制药有限公司 Nutritional compositions comprising neuroprotective dietary oligosaccharides
WO2014100022A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
MY187609A (en) 2012-12-18 2021-10-04 Abbott Lab Human milk oligosaccharides to ameliorate symptoms of stress
EP2745705A1 (en) 2012-12-18 2014-06-25 Abbott Laboratories Nutritional use of human milk oligosaccharides
EP2757162B1 (en) * 2013-01-22 2015-10-21 DMK Deutsches Milchkontor GmbH Process for increasing yield in the manufacture of lactose (II)
DK2971191T3 (en) 2013-03-15 2020-01-20 Fonterra Cooperative Group Ltd LACTOSE RECOVERY
EP3572520A1 (en) * 2013-09-10 2019-11-27 Jennewein Biotechnologie GmbH Production of oligosaccharides
WO2015041515A1 (en) * 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
EP2880993A1 (en) * 2013-12-04 2015-06-10 Abbott Laboratories Method of achieving memory and learning improvement by the administration of sialic acid
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
WO2016126810A1 (en) 2015-02-04 2016-08-11 Idaho Milk Products Process for manufacture of milk permeate powders
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function
CN109561724A (en) * 2016-06-21 2019-04-02 阿拉食品公司 The product for producing the method for the improvement nutrition product containing lactoprotein and lactose class and being obtained by this method

Also Published As

Publication number Publication date
US20200306277A1 (en) 2020-10-01
EP3490567A1 (en) 2019-06-05
MX2019000881A (en) 2019-07-01
BR112019001525B1 (en) 2022-09-06
KR20190046770A (en) 2019-05-07
SG10202100843TA (en) 2021-03-30
CN109715169A (en) 2019-05-03
US20190247409A1 (en) 2019-08-15
AU2017302181B2 (en) 2023-02-02
RU2019105567A (en) 2020-08-28
WO2018020473A1 (en) 2018-02-01
US12016869B2 (en) 2024-06-25
RU2019105567A3 (en) 2021-05-14
AU2017302181A1 (en) 2019-02-21
NZ750365A (en) 2022-07-01
EP3490567A4 (en) 2020-03-18
US10729707B2 (en) 2020-08-04
BR112019001525A2 (en) 2019-06-18
CA3030809A1 (en) 2018-02-01
JP2019523278A (en) 2019-08-22
KR102502459B1 (en) 2023-02-21

Similar Documents

Publication Publication Date Title
SG11201811807XA (en) Dairy product and process
SG11201807912SA (en) Vaccine against rsv
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201909656YA (en) Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810430WA (en) Heater assembly for an aerosol-generating system
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201808420PA (en) Method for separation of magnesium and calcium ions from saline water, for improving the quality of soft and desalinated waters
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201809051YA (en) Cell retention device and method
SG11201804143WA (en) A process and apparatus for in-line blending of polymers
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201901374WA (en) Antibiotic compounds
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide